We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Methylated MicroRNAs Prove Biomarkers for Early Detection of Cancer

By LabMedica International staff writers
Posted on 09 Sep 2019
Print article
Image: By measuring the methylation rate of microRNA, various cancer states can be detected (Photo courtesy of Osaka University).
Image: By measuring the methylation rate of microRNA, various cancer states can be detected (Photo courtesy of Osaka University).
A team of Japanese cancer researchers has shown that microRNA methylation was a more powerful indicator of early-stage pancreatic cancer than were established biomarkers, such as unmodified microRNAs.

Despite advances in cancer treatment, some 75% of all pancreatic cancer patients die within 12 months of diagnosis, including many who die within just a few months. Thus, development of new methods to detect this disease as early as possible remains an urgent priority.

In this regard, investigators at Osaka University (Japan) looked at native and methylated microRNAs as potential biomarkers for early detection of pancreatic cancer. MicroRNAs (miRNAs) and short interfering RNAs (siRNA) comprise a class of about 20 nucleotides-long RNA fragments that block gene expression by attaching to molecules of messenger RNA in a fashion that prevents them from transmitting the protein synthesizing instructions they had received from the DNA. With their capacity to fine-tune protein expression via sequence-specific interactions, miRNAs help regulate cell maintenance and differentiation. The biological significance of micro (mi)RNAs has traditionally been evaluated according to their RNA expression levels based on the assumption that miRNAs recognize and regulate their targets in an unvarying fashion.

To evaluate the potential of microRNA methylation as a biomarker for early cancer diagnosis, the investigators employed a non-targeted mass spectrometry sequencing technique that enabled unbiased detection of RNA modifications, leading to the identification of novel methylated cytosines and adenines in several mature miRNAs in cancer cell lines, human tissues, and serum.

Results revealed that a fraction of mature miRNAs including miR-17-5p, -21-5p, and -200c-3p and let-7a-5p harbored methyl marks that potentially altered their stability and target recognition. Methylation of these miRNAs was significantly increased in cancer tissues as compared to paired normal tissues. Furthermore, miR-17-5p methylation level in serum samples distinguished early pancreatic cancer patients from healthy controls with extremely high sensitivity and specificity.

"While we found methylated microRNA in the samples from pancreatic cancer patients, it was either present in very low levels or absent in the control group," said senior author Dr. Hideshi Ishii, professor of medicine at Osaka University. "Further, methylation levels in serum samples were able to distinguish early pancreatic cancer patients from healthy controls with extremely high sensitivity and specificity."

The methylated microRNA study was published in the August 29, 2019, online edition of the journal Nature Communications.

Related Links:
Osaka University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.